Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Inozyme Pharma, Inc. Banner

Inozyme Pharma, Inc.

INZY Stock Analysis

Page title

Section title

Breakdown
2001
2018
2019
2020
2021
2022
2023
Net Income
0.000-6.964m-19.724m-56.424m-56.624m-67.061m-71.169m
Depreciation & Amortization
0.00026.000K83.000K217.000K674.000K744.000K1.294M
Change in Working Capital
0.0001.431M601.000K-111.000k85.000K2.012M-3.082m
Operating Cash Flow
0.000-9.437m-18.810m-35.974m-48.153m-57.761m-70.675m
Capital Expenditure
0.000-259.000k-139.000k-568.000k-397.000k-410.000k-298.000k
Free Cash Flow
0.000-9.696m-18.949m-36.542m-48.550m-58.171m-70.973m
Debt Repayment
0.0000.0000.0000.0000.000-4.050m-40.000m
Dividends Paid
0.0000.0000.0000.0000.0000.0000.000
Common Stock Issued
0.00031.945M22.970M115.972M609.000K68.738M85.969M
Common Stock Repurchased
0.0000.0000.0000.0000.00092.000K206.000K
Net Change in Cash
0.00031.514M-4.231m-3.341m-4.724m9.599M1.673M